Company ProfilePremium

Paradigm Biopharmaceuticals Limited

Company Profile Analysis

Ticker: PAR.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Paradigm Biopharmaceuticals Limited - Company showcase

Year Founded & Workforce

2014

50 Employees

Paradigm Biopharmaceuticals Limited logo

Paradigm Biopharmaceuticals Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Paradigm Biopharmaceuticals Limited Overview

Paradigm Biopharmaceuticals is a Melbourne-based, pre-revenue drug-repurposing company that spent more than a decade developing a single molecule — pentosan polysulfate sodium (PPS), an old semi-synthetic polysaccharide derived from beech-wood xylan — as a subcutaneous injection (iPPS, branded Zilosul®) for knee osteoarthritis pain and function. The thesis was that a six-week course of injections could deliver a durable, non-opioid benefit positioned between conservative care and knee replacement, with possible structural (cartilage and bone-marrow-lesion) effects as differentiation. The company held US FDA Fast Track designation, ran a TGA Special Access Scheme generating token revenue, and in 2025 added an oral PPS-plus-COX-2 combination (Pentacoxib®) through the acquisition of Proteobioactives. Its fate was binary on the pivotal PARA_OA_012 trial. The September 2026 futility outcome, combined with secured convertible note obligations and thin net assets, pushed the company into voluntary administration, where its residual value now lies in IP, clinical data and any recapitalisation.


Company's own description (paraphrased from FY2026 Annual Report). Paradigm describes itself as a late-stage clinical development company whose purpose is to improve patients' health and quality of life by developing and delivering pharmaceutical therapies, with a vision of becoming a recognised global leader in developing and commercialising innovative therapies. Its stated principal activity is researching and developing therapeutic products for human use. Its standard boilerplate describes the current focus as developing iPPS for diseases in which inflammation plays a major pathogenic role, drawing on the anti-inflammatory and tissue-regenerative properties attributed to PPS, with osteoarthritis at Phase 3.

Independent characterisation. Paradigm was, in substance, a single-asset, single-indication repurposing biotech. PPS has a long history as an approved oral product (in some markets for interstitial cystitis) and as a veterinary injectable; Paradigm's proprietary angle was the subcutaneous human formulation, dose regimen (2 mg/kg twice weekly for six weeks), method-of-use patents, and a clinical dataset in knee OA. Third-party commentary notes that Germany's Bene Pharmachem was the sole manufacturer of the active ingredient, creating supply concentration (Stockhead, 2023).

Business model. Development-stage licensing/commercialisation model. Management's stated plan was to generate Phase 3 evidence, file an NDA with the FDA, and pursue regional and global licensing (discussions at BIO International Convention 2026). No commercial product approval was ever obtained.

Revenue model mix (FY2026).

Roughly 99% of reported income is non-operating (R&D Tax Incentive and interest). Product, service, subscription and licensing revenue: none, other than SAS access fees.

Value chain position. Clinical development sponsor. Manufacturing of API outsourced (Bene Pharmachem per press commentary); clinical operations outsourced to Advanced Clinical (global CRO) and Nordic Bioscience Clinical Development A/S (complementary CRO for imaging, biomarkers, Hong Kong and Moldova expansion).

Customer types and end-markets. Prospective: physicians (rheumatology, orthopaedics, sports medicine, primary care) treating symptomatic knee OA; payers; pharma licensing partners. Current: a small number of experienced Australian prescribers under SAS (including chronic arthralgia from Ross River virus infection). Pentacoxib® was initially targeted at veterinary applications.

Strategy

Stated strategy (FY2026 Annual Report, paraphrased). The FY2026 report framed strategy around five themes: (1) shifting from trial execution to clinical evidence generation after full recruitment; (2) funding certainty through key Phase 3 milestones via staged financing; (3) building an evidence package beyond registration (Day 112 pain, Day 168 durability and qMRI, Day 404 long-term durability); (4) positioning Zilosul® as a differentiated non-opioid therapy between conservative care and knee replacement, aligned with the FDA's May 2026 draft guidance on non-opioid analgesics; and (5) widening the PPS platform through Pentacoxib® and translational research. Management also said planning for a potential confirmatory trial had commenced and NDA, manufacturing readiness and partnering work would continue.

Initiatives in the last 24 months.

ESG commitments: none disclosed. Medium-term financial targets: none; prior guidance pointed to an Interim Analysis (September 2026) and top-line Phase 3 results (Q1 CY2027), both now superseded. The company said on 30 September 2026 that the clinical review and restructuring would take at least eight weeks.

Product Portfolio

AssetDescriptionKey specificationsTarget patient/customerStage / latest status (Oct 2026)Pricing

Zilosul® (iPPS) — knee OA

Subcutaneous injectable pentosan polysulfate sodium

2 mg/kg twice weekly for six weeks; primary endpoint weekly average daily pain (11-point NRS) at Day 112; WOMAC function secondary; quantitative MRI at Day 168 and Day 404

Adults with symptomatic knee OA with persistent pain despite conservative care

Phase 3 PARA_OA_012 interim analysis met futility (23 Sep 2026); FDA Fast Track designation retained; future path under administrators' review

Not commercialised

iPPS via TGA Special Access Scheme

Pay-for-use access for eligible patients

Restricted to experienced prescribers; includes Ross River virus chronic arthralgia and re-treatment

Australian physicians

Ongoing in FY2026 (A$80,150 revenue); status in administration not disclosed

Pay-for-use; price not disclosed

Pentacoxib®

Oral fixed combination of PPS with a selective COX-2 inhibitor

Acquired via Proteobioactives (founded by PPS pioneer Prof. Peter Ghosh); exclusive global rights

Initially veterinary; potential earlier-stage human OA

Early formulation development

Not commercialised

iPPS — mucopolysaccharidosis (MPS)

iPPS in a rare lysosomal storage disease

Previously described as Phase 2

Rare-disease patients

Not featured in FY2026 reporting; status not publicly disclosed

—

Respiratory program (Rhinosul® trademark)

PPS in respiratory/inflammatory indications

Trademark registered

—

Described in FY2025 AR as strategic for future; no active trial disclosed

—

Translational research (City St George's, University of London)

qMRI plus gene/protein profiling of tissue from knee replacement

Bone marrow lesions, cartilage, synovium

Scientific differentiation

Established FY2026

—

Financial Narrative

Income statement (A$ M; fiscal years ending 30 June).

Sources: FY2026 Annual Report (five-year income, loss, EPS; FY2026 and FY2025 line items); StockAnalysis/TipRanks (FY2022–FY2025 R&D, SG&A, operating income, EBITDA, SAS revenue). FY2026 operating income is derived from the FY2026 income statement (SAS revenue less cost of sales, R&D, G&A and commercial expense). FY2026 EBITDA is not disclosed and is left blank. Income tax is nil in all years (losses; R&D incentive booked as other income). Gross, operating, EBITDA and net margins are not meaningful (product revenue below A$0.1m; vendor-computed operating margins run to tens of thousands of percent negative). Total-income CAGR FY2022–FY2026: approximately -1.9% (derived).

Balance sheet (A$ M, 30 June).

Sources: FY2026 Annual Report (FY2025–FY2026; FY2024 restated opening equity); StockAnalysis (FY2022–FY2024 assets, cash, net cash). Blank cells: not in sources reviewed. Goodwill: nil. Total debt split: all FY2026 borrowings (convertible notes) classified current; no long-term debt other than A$0.36m non-current lease liability. Notable FY2026 movements: trade payables jumped from A$2.73m to A$17.15m, reflecting accrued Phase 3 costs — central to the later solvency crisis. Net tangible assets per share fell from 5.33 cents to 0.44 cents.

Cash flow (A$ M).

Sources: FY2026 Annual Report; TipRanks/StockAnalysis for FY2022–FY2024. FY2026 FCF derived as OCF plus investing outflows (including A$0.49m intangible/IP payment). Capex is negligible in all years. FY2026 also included A$2.25m of note redemptions and A$16.18m of notes converted into shares (non-cash).

Ratios.

All ratios derived from annual report figures; InvestSMART reports FY2026 ROE of -1,623% on closing equity (methodology difference). ROIC, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle are not meaningful for a pre-revenue, net-cash, loss-making biotech.

Commentary. The five-year record is a pure burn profile. Spending peaked in FY2023–FY2024 (R&D A$52.7m and A$58.3m) with the PARA_OA_002 program, collapsed in FY2025 (A$17.7m) during the regulatory reset and protocol re-design for a single pivotal trial, then tripled again in FY2026 (A$53.9m) as PARA_OA_012 enrolled 538 patients across 57 sites. Importantly, the company ran each pivotal phase with less than one year of cash in hand: at 30 June 2026 it held A$15.4m of cash against current liabilities of A$26.6m, including A$17.2m of payables and A$7.0m of secured notes. The going-concern basis in the FY2026 accounts relied on R&D refunds (A$13.0m receivable), the undrawn US$7m of Obsidian capacity (subject to minimum-cash and other conditions) and potential capital raisings — all of which became uncertain or unavailable once the interim analysis failed. The FY2026 finance cost of A$2.46m (from A$0.01m) shows the price of the note facility. The equity base was eroded to A$3.47m, explaining why administration followed within a week of the futility announcement.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsProducts/programs

Single segment: PPS therapeutics R&D

All operations

Zilosul® (iPPS, knee OA); SAS supply; Pentacoxib® (oral PPS + COX-2); historical MPS and respiratory (Rhinosul trademark) programs

Results by Segment and Revenue by Segment (%)

Metric (AUD Mn)FY2024FY2025FY2026

SAS product revenue

0.070.050.08

Total income incl. R&D Tax Incentive

6.447.118.13

Pre-tax loss

-58.73-18.77-56.33

Share of total income (%)

100100100

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

SAS product revenue (AUD Mn)

0.080.050.070.050.08

Total income incl. R&D Tax Incentive (AUD Mn)

8.798.586.447.118.13

Gross profit on SAS (AUD Mn)

-0.06-0.02-0.01-0.020.07

R&D expense (AUD Mn)

39.0152.6858.3317.7453.92

G&A plus commercial expense (AUD Mn)

8.857.396.775.587.26

Operating income, excl. other income (AUD Mn)

-47.93-60.09-65.11-23.34-61.12

EBITDA (AUD Mn)

-46.82-59.06-64.54-25.25—

Finance costs (AUD Mn)

0.030.020.010.012.46

Pre-tax income (AUD Mn)

-39.25-51.91-58.73-18.77-56.33

Net income (AUD Mn)

-39.25-51.91-58.73-18.77-56.33

Basic EPS (A$ cents)

-16.87-20.78-20.03-5.97-17.91

Diluted EPS (A$ cents)

-16.87-20.78-20.03-5.97-17.91

Dividends per share (A$ cents)

00000

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Cash and equivalents (AUD Mn)

39.6756.3317.8216.8215.37

Trade and other receivables (AUD Mn)

6.726.816.076.3713.06

Total current assets (AUD Mn)

47.1763.7925.2424.1329.15

Intangible assets (AUD Mn)

2.952.952.950.410.91

Total assets (AUD Mn)

50.6967.0728.3724.5730.55

Convertible notes liability (AUD Mn)

00007.00

Derivative liability (AUD Mn)

00001.65

Lease liabilities (AUD Mn)

———0.010.51

Total liabilities (AUD Mn)

———3.3927.08

Total equity (AUD Mn)

——24.7921.183.47

Net cash, cash less notes and leases (AUD Mn)

39.1056.0417.6316.817.86

Working capital (AUD Mn)

———20.892.57

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (AUD Mn)

-32.21-45.19-65.94-15.99-43.69

Investing cash flow (AUD Mn)

0000.05-0.55

Free cash flow (AUD Mn)

-32.21-45.19-65.94-15.99-44.18

Financing cash flow (AUD Mn)

0.0762.5328.1814.9943.69

Equity issue proceeds (AUD Mn)

———16.0021.57

Convertible note proceeds (AUD Mn)

000025.42

Dividends paid (AUD Mn)

00000

Buybacks (AUD Mn)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROA on average assets (%)

-57.9-88.2-123.1-70.9-204.4

ROE on average equity (%)

———-81.6-456.9

Current ratio (x)

———7.461.10

Debt to equity (x)

00002.16

Revenue by Region

RegionFY2024FY2025FY2026

Australia — SAS product revenue (AUD Mn)

0.070.050.08

Australia — R&D Tax Incentive and other income (AUD Mn)

6.387.058.05

United States revenue (AUD Mn)

000

Rest of world revenue (AUD Mn)

000

Country Overview

CountryClinical sites

United States

41

Australia

12

Moldova

3

Hong Kong

1

Share Price and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Share price at 30 June (AUD)

0.970.990.260.300.17

Dividends declared (A$ cents)

00000

Basic EPS (A$ cents)

-16.87-20.78-20.03-5.97-17.91

Analyst Conclusions

Management guidance. Pre-futility guidance (interim September 2026; top-line Q1 CY2027; NDA preparation; confirmatory trial planning) is withdrawn in substance. The only current guidance is that the clinical review and restructuring will take at least eight weeks and that the goal is a DOCA preserving IP and clinical data.

Consensus expectations. No valid post-event consensus exists.

Bull case (low probability)

  1. Missing-data imputation drove the futility outcome; a per-protocol or completer analysis might show a treatment effect worth a smaller, better-run confirmatory study, keeping Fast Track relevance.

  2. A DOCA with Obsidian or a new sponsor could recapitalise a clean shell with the IP, data and Pentacoxib® intact at low cost.

  3. Pentacoxib® in veterinary markets offers a nearer, cheaper path to revenue than human OA.

Bear case (base expectation)

  1. A pre-specified futility boundary is a strong negative signal; regulators judge the ITT analysis, not post-hoc subsets.

  2. Secured creditor priority and A$17m+ of payables mean existing shareholders likely face severe dilution or wipe-out under any DOCA.

  3. Repeated failure to secure regulatory shortcuts (FDA 2018, TGA 2025) and now Phase 3 futility will deter partners.

Catalysts and monitorables (next 12 months)

  • Outcome of 9 October 2026 creditors' meeting and committee of inspection formation.

  • Administrators' report to creditors and second meeting (DOCA vs liquidation vote).

  • Unblinded Phase 3 data review disclosures, including the size and cause of missing data.

  • Treatment of Obsidian's secured notes and any new funding proposal.

  • ASX reinstatement or delisting decision.

  • PAROB option expiry on 1 December 2026 (worthless absent reinstatement and recovery).

  • Status of the remaining R&D Tax Incentive receivable (~A$8m after the July refund) and trial wind-down costs.

Analyst verdict. Paradigm Biopharmaceuticals is a case study in the asymmetric risks of a single-asset, cash-constrained biotech. For a decade the company kept the PPS-in-osteoarthritis thesis alive through Phase 2 data, an FDA Fast Track designation, expanded-access programs and serial equity raisings, while never building more than about a year of runway. By FY2026 it had executed operationally — 538 participants, 57 sites, clean DSMB safety reviews — but did so on a balance sheet with A$3.5m of net assets, A$17m of payables and secured convertible notes whose conversion and covenant mechanics favoured the lender. The September 2026 interim analysis was therefore not merely a clinical readout but a solvency test. When the DSMB declared futility, citing a significant amount of missing data, the financing structure unravelled within a week: the last drawdown was reversed and administrators were appointed. From an equity standpoint, the investment case as previously constructed no longer exists. The relevant questions now concern recovery value: whether the IP, the Phase 3 dataset, the Fast Track status and Pentacoxib® can be packaged into a DOCA attractive enough for Obsidian or a new sponsor to fund, and what, if anything, survives for ordinary shareholders after secured and unsecured creditors. The company's claim that missing-data imputation drove the result is plausible in principle and worth understanding, but such explanations rarely rescue a futile pivotal trial in regulators' eyes without a fresh, adequately powered study — something a company in administration cannot fund. Our assessment is that the probability of meaningful equity recovery is low; any residual value is more likely to accrue to creditors and a recapitalising party. Investors and counterparties should monitor the administrators' report, the DOCA terms and the detailed data review, and treat all pre-September 2026 valuations, targets and guidance as void.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedBackgroundEducation

Paul Rennie

Founder; Managing Director and Executive Chairman

MD since 22 Nov 2022 (previously non-executive chair)

Boehringer Mannheim (now Roche Diagnostics); Merck national sales and marketing manager; Director of business development at Soltec (FH Faulding); led commercialisation of Recaldent®; inaugural COO and later EVP New Product Development at Mesoblast; director of NeuroScientific Biopharmaceuticals 2021–2023

BSc, MBM, Grad Dip Commercial Law, MSTC

Amos Meltzer

Non-Executive Director

9 Dec 2020

Scientist and IP lawyer; former General Counsel at Compugen and Gilat; former CEO of Immuron; Chief Legal Officer of Synchron; chair of Maverick LifeSciences

—

Matthew Fry

Non-Executive Director

4 Mar 2024

Founder, CEO and MD of AM Diagnostics; US expansion 2009; TGA/FDA regulatory experience

—

Dr Donna Skerrett

Chief Medical Officer (former Executive Director, 3 Jul 2020 – 20 Nov 2024)

—

Led PARA_OA_012 execution; signalled in Aug 2026 that a new CMO would be recruited

—

Abby Macnish Niven

Company Secretary (and CFO function per AR heading)

30 Aug 2022

20+ years in wealth management

BComm, BSc, CFA, GAICD

Simon White

Director of Investor Relations

—

Long-standing IR contact

—

“—” = not publicly disclosed.

Directors' Remuneration

NameSalary and feesAnnual leaveCash bonusSuperShare-based paymentsTotal

Paul Rennie

1,010,25255,868138,59629,932-947,684286,964

Amos Meltzer

82,800009,936092,736

Matthew Fry

80,000000080,000

Major Shareholders

HolderSharesApprox. % of 584.8mSource/date

Paul Rennie (director)

20,809,4253.6

FY2026 AR (Aug 2026)

Matthew Fry (director)

1,596,3000.3

FY2026 AR

Allianz Asset Management GmbH

17,372,8603.0

Simply Wall St (dated, pre-2026 dilution)

Collins St Asset Management

15,148,6922.6

Simply Wall St (dated)

RBC Global Asset Management

11,509,3782.0

Simply Wall St (dated)

Kzee Pty Ltd

11,380,9021.9

Simply Wall St (dated)

Competitive Landscape

Key Competitors

Competitor / product classModalityRelative position vs Paradigm

Oral and topical NSAIDs (multiple generics)

Standard of care

Entrenched, cheap; GI/CV safety limits — Paradigm's core positioning argument

Pacira BioSciences — Zilretta (extended-release triamcinolone)

Intra-articular steroid

Approved US product in knee OA pain

Sanofi — Synvisc family; Bioventus — Durolane; Anika Therapeutics — HA products; Ferring — Euflexxa

Hyaluronic acid injections

Established procedure-based market with variable evidence

Grünenthal — resiniferatoxin (RTX)

Intra-articular TRPV1 agonist

Late-stage OA knee pain program

Kolon TissueGene — TG-C

Cell/gene therapy

Late-stage disease-modification candidate

Biosplice — lorecivivint

Wnt pathway modulator

Late-stage OA program

Vertex — suzetrigine (Journavx)

NaV1.8 non-opioid analgesic

Approved for acute pain; competitor for "non-opioid" narrative

Cynata Therapeutics (ASX: CYP) — CYP-004

MSC therapy

ASX peer in OA

Mesoblast (ASX: MSB)

Cell therapy

ASX peer, pain/back programs

Generic PPS (Elmiron-type oral products, veterinary PPS)

Same molecule

Risk of off-label/compounded competition where patents absent

Company Snapshot

50

Employees

2014

Founded

Melbourne, Australia

Headquarters

SWOT Analysis

Strengths

  • FDA Fast Track designation for the Zilosul® OA program remains in place (ASX, 23 Sep 2026).
  • Executed a 538-patient, 57-site multinational Phase 3, exceeding the 466 target (FY2026 AR).
  • Three DSMB safety reviews (20%, 50%, 80%) raised no material safety concerns (ASX, 13 Aug 2026; FY2026 AR).
  • Repurposed molecule with long clinical history; over 1,400 people had received iPPS by 2024 (Bell Potter presentation).
  • Australian R&D Tax Incentive receivable of A$12.98m at 30 June 2026 (FY2026 AR).
  • Founder-led, with directors holding ~22.4m shares, aligning incentives (FY2026 AR).

Weaknesses

  • Single-asset dependence; interim futility on 23 Sep 2026.
  • Net assets only A$3.47m and current ratio ~1.10 at 30 Jun 2026 (FY2026 AR).
  • Trade payables of A$17.15m at year end versus cash of A$15.37m (FY2026 AR).
  • Product revenue never exceeded ~A$0.08m in five years (FY2026 AR; StockAnalysis).
  • Combined Chair/MD and only three directors; remuneration committee dissolved (FY2026 AR).
  • Significant missing data in the pivotal trial, attributed to operational challenges (ASX, 23 Sep 2026).

Opportunities

  • Post-hoc analysis of completers/pre-specified secondary endpoints could inform a smaller confirmatory design (company stated data review ongoing).
  • Pentacoxib® veterinary pathway, potentially lower cost and faster (FY2026 AR).
  • DOCA could preserve IP and clinical data for a recapitalised vehicle (Business News Australia, 30 Sep 2026).
  • Out-licensing of data/IP to a partner with OA franchise ambitions (BIO 2026 discussions).
  • SAS access for niche indications such as Ross River virus arthralgia (FY2026 AR).
  • Non-opioid policy tailwinds (FDA May 2026 draft guidance).

Threats

  • Liquidation if a DOCA is not approved by creditors.
  • Secured noteholder (Obsidian) priority over shareholders in any restructuring.
  • Likely near-total dilution or cancellation of existing equity under a DOCA (typical outcome; not yet determined).
  • Trial wind-down costs and contractual commitments to CROs and sites (ASX, 23 Sep 2026).
  • Reputational damage to the PPS-in-OA thesis complicates partnering.
  • Generic PPS availability where patents do not extend (FY2026 AR risk statement).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
May 2025Phase 3 site activation beginsStart of pivotal execution
Jun 2025Proteobioactives acquisition completedPipeline broadening
1 Jul 2025US$27m Obsidian facility; Tranche 1Funding through interim
29 Aug 2025FY2025 results: loss A$18.77m; A$2.53m impairment; restatementLower burn year
19 Nov 2025AGM; NBCD engagement; interim guided to mid-2026Strategic messaging
17 Nov 2025Tranche 2 drawdownFunding
23 Dec 2025~25% recruitmentProgress
18 Feb 2026Tranche 3 (US$5m)Funding
17–19 Feb 2026Performance rights and options granted to MDRemuneration
27 Feb 2026Half-year loss A$23.24mBurn acceleration
31 Mar 202650% enrolment; interim cohort dosingMilestone
27 Apr 2026March quarter 4CCash update
30 Apr 2026DSMB 20% safety review — continue; Moldova siteSafety
May 2026FDA draft guidance on non-opioid analgesics (cited by company)Regulatory context
Q2 2026A$14.0m placement; A$7.74m SPP; PAROB optionsDilutive funding at weak price
15 Jun 2026Enrolment complete (538); investor webinar 18 JunMilestone
Jun 2026BIO International (San Diego) partneringBusiness development
13 Jul 2026Tranche 4 (US$3m); 3m notes issuedFunding
22 Jul 2026A$4.82m FY2025 R&D refund receivedCash
30 Jul 2026June quarter 4C: cash ~A$15.37mLiquidity
13 Aug 2026DSMB 80% safety review — unchangedSafety
28 Aug 2026FY2026 results and Annual Report; CMO transition flaggedFinancial
3 Sep 2026Melbourne investor lunch announced for 23 SepIR
11 Sep 2026US$2m remaining Tranche 4 drawnFunding
23 Sep 2026Interim futility; voluntary suspension; material uncertaintyThesis-breaking event
24 Sep 2026Agreement to return US$2m to Obsidian; 2m notes cancelledCreditor management
29–30 Sep 2026FTI Consulting appointed voluntary administratorsInsolvency process
9 Oct 2026First creditors' meeting scheduledOutcome not yet reported in sources reviewed

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: SAS product revenue held from AUD 0.1 Mn in FY2022 to AUD 0.1 Mn in FY2026.
Paradigm Biopharmaceuticals Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
SAS product revenue0.10.10.10.10.1
Gross profit on SAS-0.1-0-0-00.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Paradigm FY2026 Appendix 4E and Annual Report (28 Aug 2026) (bulletin.webull.com)
  2. ASX release, Phase 3 Interim Result Below Continuation Threshold (23 Sep 2026) (announcements.asx.com.au)
  3. FTI Consulting, Appointment of Voluntary Administrators (30 Sep 2026) (announcements.asx.com.au)
  4. Business News Australia, administrators appointed (30 Sep 2026) (businessnewsaustralia.com)
  5. ASX release, Agreement to Return US$2M to Obsidian (24 Sep 2026) (investorpa.com)
  6. ASX release, Tranche 4 balance drawdown (11 Sep 2026) (investorpa.com)
  7. ASX release, 80% safety review (13 Aug 2026) (announcements.asx.com.au)
  8. ASX release, Tranche 4 drawdown (13 Jul 2026) (announcements.asx.com.au)
  9. ASX release, enrolment complete (15 Jun 2026) (announcements.asx.com.au)
  10. ASX release, DSMB 20% review and Moldova (30 Apr 2026) (announcements.asx.com.au)
  11. ASX release, 50% enrolment (31 Mar 2026) (announcements.asx.com.au)
  12. ASX Appendix 4D half-year (27 Feb 2026) (announcements.asx.com.au)
  13. ASX release, Tranche 3 (18 Feb 2026) (announcements.asx.com.au)
  14. ASX release, 25% recruitment (23 Dec 2025) (announcements.asx.com.au)
  15. 2025 AGM address (19 Nov 2025) (bulletin.webull.com)
  16. FY2025 Annual Report (29 Aug 2025) (announcements.asx.com.au)
  17. Obsidian facility announcement (1 Jul 2025) (announcements.asx.com.au)
  18. Stockhead, Proteobioactives acquisition (stockhead.com.au)
  19. Stockhead, FDA protocol review concluded (Nov 2024) (stockhead.com.au)
  20. Stocks Down Under, TGA provisional determination outcome (stocksdownunder.com)
  21. Biotech Daily (3 Nov 2023) (biotechdaily.com.au)
  22. Edison Research (Oct and Nov 2023) (edisongroup.com)
  23. Bell Potter company presentation (Nov 2024) (bellpotter.com.au)
  24. SmallCaps, NFL expanded access and TGA pathway (smallcaps.com.au)
  25. StockAnalysis income statement and balance sheet (stockanalysis.com)
  26. TipRanks income statement and cash flow (tipranks.com)
  27. InvestSMART PAR profile and financials (investsmart.com.au)
  28. Simply Wall St ownership and forecasts (simplywall.st)
  29. FNArena PAR consensus (fnarena.com)
  30. Kalkine Media, convertible note issue (13 Jul 2026) (kalkinemedia.com)
  31. Motley Fool via Tiger, Dec 2024 trading halt (itiger.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.